Your browser is no longer supported. Please, upgrade your browser.
Reneo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own14.20% Shs Outstand23.70M Perf Week-10.20%
Market Cap194.10M Forward P/E- EPS next Y-2.47 Insider Trans153.40% Shs Float23.54M Perf Month-12.22%
Income- PEG- EPS next Q-0.38 Inst Own60.90% Short Float4.90% Perf Quarter-43.13%
Sales- P/S- EPS this Y-56.50% Inst Trans- Short Ratio16.25 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh3.85 P/C2.13 EPS next 5Y- ROE- 52W Range7.63 - 17.18 Perf YTD-41.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.33% Beta-
Dividend %- Quick Ratio23.80 Sales past 5Y- Gross Margin- 52W Low7.34% ATR0.55
Employees16 Current Ratio23.80 Sales Q/Q- Oper. Margin- RSI (14)38.14 Volatility5.46% 5.59%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.26 Prev Close8.46
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume70.94K Price8.19
Recom- SMA20-7.59% SMA50-13.11% SMA200-22.49% Volume18,371 Change-3.19%
May-04-21Initiated SVB Leerink Outperform $25
May-04-21Initiated Piper Sandler Overweight $45
May-04-21Initiated Jefferies Buy $24
Jul-28-21 08:00AM  
Jul-12-21 09:30AM  
Jul-09-21 08:00AM  
Jul-07-21 08:00AM  
Jun-29-21 08:00AM  
May-20-21 06:00AM  
May-19-21 06:00AM  
Apr-13-21 08:14AM  
Apr-09-21 12:32PM  
Apr-08-21 09:42PM  
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Muralidhar BaliDirectorJul 14Buy8.50111,736949,7562,073,957Jul 15 05:34 PM
Johnson Wendy S.Chief Development OfficerJul 14Sale8.50111,736949,7560Jul 15 05:33 PM
Johnson Wendy S.Chief Development OfficerJul 08Option Exercise1.97111,736220,120111,736Jul 09 06:52 PM
Muralidhar BaliDirectorJun 23Buy9.2820,710192,2451,962,221Jun 25 09:00 AM
Muralidhar BaliDirectorJun 22Buy8.7214,615127,4871,941,511Jun 23 08:33 AM
Muralidhar BaliDirectorJun 21Buy9.0332,659294,9271,926,896Jun 23 08:33 AM
Muralidhar BaliDirectorJun 08Buy9.5016,605157,7091,894,237Jun 10 09:00 AM
Muralidhar BaliDirectorJun 04Buy9.422572,4221,877,632Jun 07 08:53 AM
Muralidhar BaliDirectorJun 03Buy9.2512,100111,9431,877,375Jun 07 08:53 AM
Muralidhar BaliDirectorMay 28Buy9.50141331,865,275Jun 02 10:37 AM
Muralidhar BaliDirectorMay 27Buy9.261,12010,3691,865,261May 28 04:10 PM
Muralidhar BaliDirectorMay 26Buy9.385,91555,4951,864,141May 28 04:10 PM
New Enterprise Associates 15, 10% OwnerApr 13Buy15.00666,6669,999,9904,785,494Apr 15 06:16 PM
O'Donnell NiallDirectorApr 13Buy15.00200,0003,000,0002,063,713Apr 15 04:16 PM
Muralidhar BaliDirectorApr 13Buy15.00200,0003,000,0001,858,226Apr 15 04:15 PM
Novo Holdings A/S10% OwnerApr 13Buy15.00666,6669,999,9903,430,377Apr 14 04:44 PM
RiverVest Venture Fund III, L.10% OwnerApr 09Buy15.00200,0003,000,0002,409,220Apr 13 05:54 PM